Prospective Biomarkers of Bone Metabolism in Hemophilia A
Status:
Completed
Trial end date:
2018-04-16
Target enrollment:
Participant gender:
Summary
One of the major shortcomings in studying bone disease in hemophilia is the lack of fracture
outcome data demonstrating the clinical significance of decreased BMD and altered bone
biomarkers in the hemophilia population. This study demonstrates that PwH have an increased
risk of fracture compared to the general population and that the issue of bone health will
increase in importance as the PwH population ages.